Thus, HSP90 inhibitors like geldanamycin or zelavespib (PU‐H71) have proven their value in the treatment of myeloma and other cancers [48], as well as in murine models of JAK2‐V617F and MPL driven MPNs. This evidence concerns the gene JAK2 and plasma cell myeloma.